TRUFF Quote, Financials, Valuation and Earnings

Aurinia Pharmaceuticals, Inc. has a net margin of -157.79% compared to Red Light Holland Corp.'s net margin of 42.95%. Red Light Holland Corp.'s return on equity of -25.54% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.

Red Light Holland Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 7.32%. Given that Aurinia Pharmaceuticals, Inc. has higher upside potential than Red Light Holland Corp., analysts believe Aurinia Pharmaceuticals, Inc. is more attractive than Red Light Holland Corp..

Red Light Holland Corp. has a beta of 1.840, which suggesting that the stock is 84.024% more volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.425, suggesting its more volatile than the S&P 500 by 42.546%.

Red Light Holland Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Red Light Holland Corp. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Red Light Holland Corp. quarterly revenues are $547.5K, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. Red Light Holland Corp.'s net income of -$863.9K is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, Red Light Holland Corp.'s price-to-earnings ratio is -- while Aurinia Pharmaceuticals, Inc.'s PE ratio is 27.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Red Light Holland Corp. is 2.52x versus 8.24x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Instadose Pharma Corp. has a net margin of -157.79% compared to Red Light Holland Corp.'s net margin of --. Red Light Holland Corp.'s return on equity of -25.54% beat Instadose Pharma Corp.'s return on equity of --.

Red Light Holland Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Instadose Pharma Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Red Light Holland Corp. has higher upside potential than Instadose Pharma Corp., analysts believe Red Light Holland Corp. is more attractive than Instadose Pharma Corp..

Red Light Holland Corp. has a beta of 1.840, which suggesting that the stock is 84.024% more volatile than S&P 500. In comparison Instadose Pharma Corp. has a beta of -714.392, suggesting its less volatile than the S&P 500 by 71539.203%.

Red Light Holland Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Instadose Pharma Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Red Light Holland Corp. pays -- of its earnings as a dividend. Instadose Pharma Corp. pays out -- of its earnings as a dividend.

Red Light Holland Corp. quarterly revenues are $547.5K, which are larger than Instadose Pharma Corp. quarterly revenues of --. Red Light Holland Corp.'s net income of -$863.9K is higher than Instadose Pharma Corp.'s net income of --. Notably, Red Light Holland Corp.'s price-to-earnings ratio is -- while Instadose Pharma Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Red Light Holland Corp. is 2.52x versus -- for Instadose Pharma Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of -157.79% compared to Red Light Holland Corp.'s net margin of --. Red Light Holland Corp.'s return on equity of -25.54% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

Red Light Holland Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.49 which suggests that it could grow by 461.59%. Given that Oncolytics Biotech, Inc. has higher upside potential than Red Light Holland Corp., analysts believe Oncolytics Biotech, Inc. is more attractive than Red Light Holland Corp..

Red Light Holland Corp. has a beta of 1.840, which suggesting that the stock is 84.024% more volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.

Red Light Holland Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Red Light Holland Corp. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

Red Light Holland Corp. quarterly revenues are $547.5K, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. Red Light Holland Corp.'s net income of -$863.9K is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Red Light Holland Corp.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Red Light Holland Corp. is 2.52x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Venus Concept, Inc. has a net margin of -157.79% compared to Red Light Holland Corp.'s net margin of -163.68%. Red Light Holland Corp.'s return on equity of -25.54% beat Venus Concept, Inc.'s return on equity of -1236.95%.

Red Light Holland Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Venus Concept, Inc. has an analysts' consensus of -- which suggests that it could grow by 5941.45%. Given that Venus Concept, Inc. has higher upside potential than Red Light Holland Corp., analysts believe Venus Concept, Inc. is more attractive than Red Light Holland Corp..

Red Light Holland Corp. has a beta of 1.840, which suggesting that the stock is 84.024% more volatile than S&P 500. In comparison Venus Concept, Inc. has a beta of -0.111, suggesting its less volatile than the S&P 500 by 111.094%.

Red Light Holland Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Venus Concept, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Red Light Holland Corp. pays -- of its earnings as a dividend. Venus Concept, Inc. pays out -- of its earnings as a dividend.

Red Light Holland Corp. quarterly revenues are $547.5K, which are smaller than Venus Concept, Inc. quarterly revenues of $13.8M. Red Light Holland Corp.'s net income of -$863.9K is higher than Venus Concept, Inc.'s net income of -$22.5M. Notably, Red Light Holland Corp.'s price-to-earnings ratio is -- while Venus Concept, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Red Light Holland Corp. is 2.52x versus 0.04x for Venus Concept, Inc.. Usually stocks with elevated PS ratios are considered overvalued.